| abstract |
The use of an Hsp90 inhibitor for the treatment of cancer of the bladder, colon, liver, lung, breast, vagina, ovaries, pancreas, kidney, stomach, gastrointestinal tract, prostate, head and neck, peritoneal cavity, thyroid, bone, brain, central nervous system and / or blood, and / or for the treatment of myelodysplastic syndrome, systemic mastocytosis, von Hippel-Lindau syndrome, disease of multicentric Castleman, and / or psoriasis. |